Efficacy and Safety of Weekly Alendronate Plus Vitamin D3 5600 IU versus Weekly Alendronate Alone in Korean Osteoporotic Women: 16-Week Randomized Trial

다국어 초록 (Multilingual Abstract)

Vitamin D (vit-D) is essential for bone health, although many osteoporosis patients have low levels of 25-hydroxy-vit-D [25(OH)D]. This randomized, open-label study compared the effects of once weekly alendronate 70 mg containing 5600 IU vit-D3 (ALN/D5600) to alendronate 70 mg without additional vit-D (ALN) on the percent of patients with vit-D insufficiency [25(OH)D <15 ng/mL, primary endpoint]and serum parathyroid hormone (PTH, secondary endpoint) levels in postmenopausal,osteoporotic Korean women. Neuromuscular function was also measured. A total of 268 subjects were randomized. Overall, 35% of patients had vit-D insufficiency at baseline. After 16-weeks, there were fewer patients with vit-D insufficiencyin the ALN/D5600 group (1.47%) than in the ALN group (41.67%) (p<0.001). Patients receiving ALN/D5600 compared with ALN were at a significantlydecreased risk of vit-D insufficiency [odds ratio=0.02, 95% confidence interval(CI) 0.00-0.08]. In the ALN/D5600 group, significant increases in serum 25(OH) D were observed at weeks 8 (9.60 ng/mL) and 16 (11.41 ng/mL), where as a significant decrease was recorded in the ALN group at week 16 (-1.61 ng/mL). By multiple regression analysis, major determinants of increases in serum 25(OH) lumDwere ALN/D5600 administration, seasonal variation, and baseline 25(OH)D. The least squares mean percent change from baseline in serum PTH in the ALN/D5600 group (8.17%) was lower than that in the ALN group (29.98%) (p=0.0091). There was no significant difference between treatment groups in neuromuscular function. Overall safety was similar between groups. In conclusion, the administrationof 5600 IU vit-D in the ALN/D5600 group improved vit-D status and reduced the magnitude of PTH increase without significant side-effects after 16 weeks in Korean osteoporotic patients.

참고문헌 (Reference)

• 1 장숙랑, "춘천지역 폐경 후 여성의 골다공증 유병률과 관련 요인 : 한림노년연구" 대한예방의학회 39 (39): 389-396, 2006
• 2 Adami S, "Vitamin D status and response to treatment in post-menopausal osteoporosis" 20 : 239-244, 2009
• 3 Lim SK, "Vitamin D inadequacy in postmenopausal women in Eastern Asia" 24 : 99-106, 2008
• 4 Holick MF, "Vitamin D deficiency: a worldwide problem with health consequences" 87 : 1080S-1086S, 2008
• 5 Holick MF, "Vitamin D deficiency" 357 : 266-281, 2007
• 6 Pfeifer M, "Vitamin D and muscle function" 13 : 187-194, 2002
• 7 Lips P, "The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects" 67 : 644-650, 1988
• 8 구지훈, "The Effects of Combined Treatment of Alendronate Plus Active or Plain Vitamin D on the Vitamin D Metabolism and Bone Turnover Markers in Patients with Osteoporosis" 대한내분비학회 25 (25): 305-309, 2010
• 9 Holick MF, "Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease" 80 (80): 1678S-1688S, 2004
• 10 이상호, "Subsequent Hip Fracture in Osteoporotic Hip Fracture Patients" 연세대학교의과대학 53 (53): 1005-1009, 2012
• 11 Institute of Medicine (U.S.), "Subcommittee on Interpretation, Uses of Dietary Reference Intakes. Dietary reference intakes. a report of the Subcommittee on Interpretation and Uses of Dietary Reference Intakes and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Applications in dietary assessment" National Academy Press 2001
• 12 Rizzoli R, "Risk factors for vitamin D inadequacy among women with osteoporosis: an international epidemiological study" 60 : 1013-1019, 2006
• 13 Shin CS, "Prevalence and risk factors of osteoporosis in Korea: A community-based cohort study with lumbar spine and hip bone mineral density" ELSEVIER SCIENCE INC 47 : 378-387, 2010
• 14 National Osteoporosis Foundation, "Physician’s guide to prevention and treatment of osteoporosis. 2nd ed" National Osteoporosis Foundation 2003
• 15 DeLuca HF, "Overview of general physiologic features and functions of vitamin D" 80 (80): 1689S-1696S, 2004
• 16 Center JR, "Mortality after all major types of osteoporotic fracture in men and women: an observational study" 353 : 878-882, 1999
• 17 Guralnik JM, "Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability" 332 : 556-561, 1995
• 18 Holick MF, "High prevalence of vitamin D inadequacy and implications for health" 81 : 353-373, 2006
• 19 Bischoff-Ferrari HA, "Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials" 293 : 2257-2264, 2005
• 20 정종관, "Fracture Incidence and Risk of Osteoporosis in Female Type 2 Diabetic Patients in Korea" 대한당뇨병학회 36 (36): 144-150, 2012
• 21 Shi N, "Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures" 45 : 1084-1090, 2009
• 22 Horwitz MJ, "Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D" 20 : 1792-1803, 2005
• 23 Wang YH, "Comparison of the action of transient and continuous PTH on primary osteoblast cultures expressing differentiation stage-specific GFP" 20 : 5-14, 2005
• 24 Drake MT, "Bisphosphonates: mechanism of action and role in clinical practice" 83 : 1032-1045, 2008
• 25 Vasikaran SD, "Bisphosphonates: an overview with special reference to alendronate" 38 (38): 608-623, 2001
• 26 Johnell O, "An estimate of the worldwide prevalence and disability associated with osteoporotic fractures" 17 : 1726-1733, 2006
• 27 Recker R, "Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial" 22 : 1745-1755, 2006
• 28 Guralnik JM, "A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission" 49 : M85-M94, 1994
• 29 van Etten E, "1,25-dihydroxycholecalciferol: endocrinology meets the immune system" 61 : 375-380, 2002